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Canonical Wnt signaling is an osteo-inductive signal that promotes bone repair 
through acceleration of osteogenic differentiation by progenitors [1-12]. Dkk-1 is a 
secreted inhibitor of canonical Wnt signaling [13-17] and thus inhibits osteogenesis 
[18-21]. To examine a potential osteo-inhibitory role of Dkk-1 in osteosarcoma (OS), 
we measured serum Dkk-1 in pediatric patients with OS (median age, 13.4 years) 
and found it to be significantly elevated. We also found that Dkk-1 was maximally 
expressed by the OS cells at the tumor periphery and in vitro Dkk-1 and RANKL 
are co-expressed by rapidly proliferating OS cells. Both Dkk-1 and conditioned 
media from OS cells reduces osteogenesis by human mesenchymal cells and by 
immuno-depletion of Dkk-1, or by adding a GSK3β inhibitor, the effects of Dkk-1 
were attenuated. In mice, we found that the expression of Dkk-1 from implanted 
tumors was similar to the human tumor biopsies in that human Dkk-1 was present 
in the serum of recipient animals. These data demonstrate that systemic levels of 
Dkk-1 are elevated in osteosarcoma. Furthermore, the expression of Dkk-1 by the 
OS cells at the periphery of the tumor probably contributes to its expansion by 
inhibiting repair of the surrounding bone. These data demonstrate that Dkk-1 may 
serve as a prognostic or diagnostic marker for evaluation of OS and furthermore, 
immuno-depletion of Dkk-1 or administration of GSK3β inhibitors could represent 
an adjunct therapy for this disease. 
 
We measured the levels of Dkk-1 in the serum of newly diagnosed individuals 
with OS by ELISA and found that, the mean levels were elevated (p<0.0001, 2 sample t-
test) in affected individuals (range, 16.84 ng mL-1 to 2210.14 ng mL-1, mean 191.91 ng 
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mL-1, median 90.53 ng mL-1) when compared to unaffected individuals (range, 2.28 ng 
mL-1 to 43.38 ng mL-1, mean 21.66 ng mL-1, median 19.67 ng mL-1). Although the 
control group (n=12) was smaller than the OS group (n=37), and the median age of the 
unaffected individuals was slightly higher (by approximately 7 years), the control Dkk-1 
values were similar to the normal levels reported by Tian et al. [20] who demonstrated 
that elevated levels of serum Dkk-1 were co-incident with the osteolytic lesions seen in 
most cases of multiple myeloma (Fig.1a). The Dkk-1 levels in the affected individuals 
were somewhat higher than those documented in the Tian et al. study with the highest 
levels in the micromolar range. Immunohistochemical staining of excised tumor biopsies 
demonstrated that Dkk-1 was expressed maximally at the periphery of the tumor, 
adjacent to the hosts’ bone tissue (Fig.1b). The expression of Dkk-1 by two osteosarcoma 
cell lines; MG63, a well-characterized osteogenic sarcoma and LS1, a cell line derived 
from an excised osteosarcoma, was examined in more detail in tissue culture 
experiments. Dkk-1 was found to be maximally secreted by cells rapidly proliferating in 
sparsely populated monolayers but was significantly reduced as proliferation slowed and 
the monolayer became more confluent (Fig.1c-d). Interestingly, Dkk-1 expression in the 
higher density monolayers was confined to a small fraction of cells that were clearly in 
the metaphase of division (Fig.1d). Also the potent upregulator of osteoclast activity, 
RANK ligand (RANKL) [22] mirrored the expression of Dkk-1 in OS cells but it was 
exclusively detected as the membrane bound form rather than the secreted form 
(Fig.1e,f). Based on these observations, we hypothesized that the expression of Dkk-1 
and RANKL at the periphery of the tumor was necessary for osteogenic remodeling as 
the tumor expands. The presence of high levels of Dkk-1 and RANKL facilitate 
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expansion by allowing the proliferative cells at the periphery of the tumor to accelerate 
bone resorption through expression of RANKL whilst inhibiting osteoid repair through 
the action of Dkk-1. 
The putative osteo-inhibitory effect of recombinant Dkk-1 was tested in a tissue 
culture model of osteogenic differentiation by human primary mesenchymal stem cells 
(MSCs) [21]. At concentrations equivalent to those measured in OS patients, Dkk-1 
inhibited the expression of the osteogenic marker, alkaline phosphatase, by MSCs in a 
dose dependent manner when added to osteogenic cultures (Fig.2a). The effect was 
observed in MSCs from 3 donors and pooled murine MSCs. In 2 donors (Fig.2a), MSCs 
cultured directly from bone spicules (red) were more resistant to Dkk-1 than those 
cultured from the fluid component of the marrow (black) suggesting that the MSCs were 
probably osteogenically pre-conditioned by the niche of the bone tissue. The observation 
that serum alkaline phosphatase is occasionally upregulated in osteosarcoma patients, 
suggests that Dkk-1 acts to prevent differentiation of progenitor cells, but does not affect 
the release of alkaline phosphatase from pre-existing osteoblasts at sites of bone 
remodeling. 
When media was conditioned by MG-63 OS cells and added to osteogenic 
cultures of MSCs, osteogenic inhibition occurred (Fig.2c) and this effect was attenuated 
upon immuno-depletion of Dkk-1 from the medium (Fig.2b,c). Dkk-1 inhibits the Wnt 
pathway by sequestering the Wnt co-receptor, LRP6 and preventing the Wnt-induced 
coalescence of Frizzled and LRP6 at the membrane. The downstream effect of the 
LRP6/Wnt/Frizzled complex is to inhibit glycogen synthetase kinase 3 beta 
(GSK3β), reduce phosphorylation of β-catenin and prevent its degradation by the 
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proteosomal machinery. Stabilized β-catenin complexes with TCF/LEF mediates 
transcription of target genes, in this case, osteogenic genes. The presence of a 
pharmaceutical inhibitor of GSK3β would be predicted to elicit the same effect as Wnt 
signaling, irrespective of the level of Dkk-1 in the system. Osteogenic cultures were 
prepared in the presence of Dkk-1 with or without the GSK3β inhibitor, bromo-indirubin-
3’-mono-oxime (BIO). The presence of BIO reduced the osteo-inhibitory effect of Dkk-1 
(Fig.2d). Since Wnt signaling has been implicated in the induction of oncogenesis, we 
tested the effect of escalating doses of BIO on MG-63 and LS-1 cell proliferation. At the 
concentrations tested, there was no significant induction of proliferation by BIO (Fig.2e).  
 We established an osteosarcoma model to recapitulate some of the effects of Dkk-
1 and OS in vivo. MG-63 cells were labeled by lentiviral transduction of a fusion gene 
combining the mitochondrial localization sequence of cytochrome c oxidase with the 
fluorescent protein, dsRed (Fig.3a,b). Upon suspension culture in the presence of clotted 
human plasma, after 24-48 hours the cells formed tumor spheroids that ranged from 
approximately 10 to 5000 cells in diameter within the fibrin gel. Smaller spheroids 
expressed Dkk-1 throughout (Fig.3d), but the larger structures adopted an expression 
pattern for Dkk-1 that mimicked the tumor biopsies (Fig.3e) with the maximal level of 
expression at the periphery. To examine the expression and distribution of Dkk-1 
expression by osteosarcoma cells in vivo, fibrin constructs containing 1 million and 10 
million labeled MG63 cells were implanted in nude mice against the upper thoracic 
vertebrae. After 1 week, the constructs were clearly visible by live animal fluorescent 
imaging (Fig.4a). Furthermore, human Dkk-1 could be detected in the blood of implanted 
animals when assayed by ELISA (Fig.4b) and the level of circulating Dkk-1 correlated 
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with the number of surviving cells in the construct. After 2 and 4 weeks post 
implantation, the number of MG63 cells present in the recipients had reduced resulting in 
a concomitant reduction of systemic Dkk-1 (data not shown). The reason for the reduced 
viability of the cells over extended implantation periods is unclear but macrophage 
mediated destruction of implants in immuno-compromised mice has been reported in the 
literature [23]. In spite of the hosts’ response to the implanted cells, human Dkk-1 could 
be detected in the blood of the recipient mice, demonstrating that tumor-derived Dkk-1 
escapes into the blood stream. It is unclear at this point whether the elevated systemic 
Dkk-1 in OS patients is derived solely from the tumor, since the human Dkk-1 circulating 
in the blood of recipient mice was much lower than the mean levels detected in the blood 
of the human OS patients. It is possible, however, that the host tissue interacts with the 
tumor resulting in upregulation of the expression of Dkk-1, a phenomenon observed in 
the case of multiple myeloma [21]. The host microenvironment in the patients may be 
more readily affected by the tumor than the surrounding mouse tissue accounting for the 
reduced levels of Dkk-1 in the mouse blood when compared to the human blood. At any 
rate, the presence of OS cells in both humans and the recipient mice resulted in elevated 
circulating human Dkk-1, suggesting that the molecule could represent a valuable 
diagnostic tool. The correlation of tumor load with Dkk-1 levels also suggests that the 
assay also has potential for measuring the relative size and severity of such tumors.  
 These data strongly suggest that the secretion of the canonical Wnt inhibitor Dkk-
1 is highly expressed by OS tumors at levels that become detectable in the systemic 
circulation in humans. Furthermore, the in vivo data demonstrates that the level of Dkk-1 
detectable in blood is proportional to the number of surviving OS cells in the tumor. 
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Assays of Dkk-1 secretion could therefore represent a useful diagnostic and prognostic 
tool for the evaluation of OS patients. Serum Dkk-1 measurements may be useful for the 
evaluation of other types of malignancy but presently it is unclear whether the expression 
is confined solely to osteolytic tumors. This certainly seems feasible since a recent study 
has demonstrated that prostate tumors that express high levels of Dkk-1 produce more 
extensive local bone destruction [24]. Reducing the osteoinhibitory effects of Dkk-1 
would be predicted to reduce local bone damage, and as a result, probably reduce the 
expansion of the tumor. This could be achieved by pharmaceutical inhibition of GSK3β 
or by antibody mediated sequestration of Dkk-1. The osteoinductive properties of GSK3β 
inhibitors have been demonstrated both in vivo and in vitro by numerous investigators 
[25] and the benefits of administration of an anti-Dkk-1 antibody has been demonstrated 
recently in a murine model of multiple myeloma [26]. However, it remains to be seen 
whether the induction of Wnt signaling either by GSK3β inhibition, or by antibody 
administration may affect the metastatic potential of OS cells since Wnt signaling and/or 
beta catenin upregulation has been shown to be a key regulator of migration in prostate 
tumors, multiple myeloma cells and also in OS cells [24, 27, 28]. Since tumor derived 
Dkk-1 was present in the blood of mice at levels proportional to the number of surviving 
tumor cells, Dkk-1 may also serve as a prognostic or diagnostic marker for evaluation of 
patients with OS. 
 
Materials and methods. 
 
Human biomaterial acquisition. The handling and acquisition of human derived 
biomaterials were performed in accordance with the institutional review boards of Tulane 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
07
.1
30
.1
 : 
Po
st
ed
 2
0 
Ju
n 
20
07
University Hospital and Clinic (New Orleans, Louisiana, USA) and St. Jude Children’s 
Hospital (Memphis, Tennessee, USA). The OS serum samples were acquired from the 
Tissue Bank of St. Jude Children’s Hospital, and the control group samples were 
collected from unaffected individuals at Tulane University Hospital and Clinic. Human 
mesenchymal stem cells were acquired from the Tulane Adult MSC Distribution Core 
(Tulane University, New Orleans, LA) and cultured in accordance with their protocols. 
 
ELISA assays. Frozen serum samples from newly diagnosed patients with OS were 
acquired from St. Jude Children’s Hospital under the supervision of Dr. N. Daw and Dr. 
E. Horwitz. Serum samples from unaffected individuals were drawn and prepared at 
Tulane University Hospital and Clinic. ELISA assays were performed as previously 
described [21].  
 
Histology and immunocytochemistry. Osteosarcoma tumors, synthetic tumor constructs 
or monolayer cells were fixed in formalin and processed as paraffin blocks if necessary. 
For histochemistry, 8 µm sections were prepared, deparaffinized and rehydrated. After an 
acidic antigen retrieval step (R and D Systems, Minneapolis, MN), sections were blocked 
and incubated in the presence of a 1:800 dilution of goat anti-human Dkk-1 or 
monoclonal anti RANKL antibody (R and D Systems). Monolayer cultures were directly 
subjected to immunocytochemistry after fixation. Alexafluor 594 or 488 conjugated 
secondary (Invitrogen, Carlsbad, CA) antibodies were employed to detect antigen 
binding. 
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Alkaline phosphatase assays. Monolayer phosphatase assays were performed on 
monolayers in 6-well format as previously described [21]. Dkk-1 preparation and culture 
conditions were as previously described [21]. BIO was acquired commercially 
(Calbiochem, LaJolla, CA). 
 
Cell counting assays. Cells were counted based on nucleic intercalation of a fluorescent 
dye (CyQuant, Invitrogen). Assays were performed as previously described [21, 29]. 
 
Western blotting. Western blots were performed on Triton X100 (Sigma, Poole, UK) 
insoluble extracts of cells using the goat anti-human Dkk-1 or monoclonal anti RANKL 
antibody (R and D Systems). Controls for actin and GAPDH were employed as 
previously described [30]. 
 
Immunoaffinity depletion. Dkk-1 was depleted from the medium by antibody 
incubation and protein A mediated depletion as previously described [29]. 
 
Cell labeling. The lentiviral construct encoding the dsRed fluorescent protein coupled to 
the mitochondrial localization sequence of human cytochrome C oxidase subunit VIII 
was prepared using standard protocols by virus core facility at Louisiana State University 
viral vector core [31,32]. Proliferating MG63 cells were exposed to the virus at a 
multiplicity of infection of 80 in the presence of 9 µg mL-1 polybrene for 18 hours. After 
4 days, approximately 50% of the cells expressed the fluorescent protein. Expressing 
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cells were selected by fluorescent activated cell sorting (Facsvantage SE, Becton 
Dickinson).  
 
Constructs. Labeled cells were suspended in 1 mL of a 2x reconstitution of dried human 
plasma (Sigma) and mixed with an equal volume of thromboplastin C (Plastinex, Fisher 
Lifesciences, Pittsburg, PA). The mixture was transferred to a 10 mm x 20 mm chamber 
slide for gelling. Clotting was allowed to proceed for 2-4 hr, and then the appropriate 
experimental medium preparation was added to cover the solid construct until 
implantation. 
 
Implantation. Fibrin constructs were implanted subcutaneously between the scapulae of 
anaesthetized nude mice. A 10 mm incision was made longitudinally between the 
scapulae and a small cavity was made between the dermis of the skin and the fascia 
below to accommodate the constructs which were 10 mm square. The incision was then 
closed by 2-3 sutures, and sealed (Vetbond, 3M, St. Paul, MN). After 5 days, the sutures 
were removed. Seven days thereafter, the animals were placed under anesthesia, 
euthanized by cardiac exsanguination, and serum was prepared from the blood. The 
implants were removed for genomic DNA extraction. Genomic DNA was extracted from 
the tissue by phenol chloroform extraction (Trizol, Invitrogen) and subjected to 
quantitative real time PCR for the dsRed gene using the following primers: forward; 
ACTACAAGAAGCTGTCCTTCC and reverse; TTCACGCCGATGAACTTCACC. 
Reactions were cycled on an ABI PRISM 7700 Sequence Detector (Applied Biosystems) 
for 40 cycles with the annealing temperature set to 60oC. Products were detected by 
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fluorescence intercalation (SYBR Green, Applied Biosystems) and validated by gel 
electrophoresis and melting curve analysis. 
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Figure legends. 
 
Figure 1: Panel a: Scatter plot of the circulating Dkk-1 levels in OS patients and 
unaffected individuals. Measurements were performed by ELISA assay. For statistical 
values, see text. Panel b: A sectioned osteosarcoma immuno-stained for the detection of 
Dkk-1 (red). Dkk-1 expression is maximal at the border zone between the osteoid tissue 
(green autofluorescence) and the tumor cells (white dotted line). Nuclei are stained with 
DAPI (blue) Panel c: Secretion of Dkk-1 by rapidly dividing, low density cultures (log) 
and slowly dividing confluent cultures (slow) of MG63 and LS1 osteosarcoma cells. 
Measurements were achieved by ELISA assay, values represent the mean (n=6), and 
error bars represent standard deviations. P values were calculated by 2-tailed Student’s t-
test. Panel d: Monolayers of MG63 cells at high (slow) and low (log) density 
immunostained for Dkk-1. Note that staining is maximal in the low density cultures and 
in the high density cultures, Dkk-1 staining is confined to those cells undergoing mitosis 
(arrowed). The DNA is stained with DAPI (blue). Panel e: Western blot of membrane 
isolates derived from MG63 and LS1 osteosarcoma cells. The control lanes (upper) were 
simultaneously incubated with an anti-β-actin and anti-GAPDH antibodies since 
enrichment for insoluble, membrane bound, β-actin confirms that the membranes have 
been efficiently recovered at the expense of cytosolic components such as GAPDH. 
Membrane bound RANKL was detected on the same stripped blot (lower) with an anti 
RANKL antibody. Panel f: Monolayers of non-permeablised MG63 cells at high (slow) 
and low (log) density immunostained for RANKL. Note that staining is maximal in the 
low density cultures and punctuate in the high density cultures. The DNA is stained with 
DAPI (blue).  
 
Figure 2: Panel a: Osteogenic differentiation of MSCs in the presence of Dkk-1. Results 
from cells derived from 3 human donors and pooled murine donors are presented. 
Osteogenic differentiation is presented as a function of membrane ALP activity, an early 
marker of osteogenesis. Measurements are normalized to control levels of activity, 
designated 1.0. The black lines represent MSCs prepared from the fluid component of 
bone marrow and the red lines represent MSCs prepared from bone spicules filtered from 
the aspirates. Dkk-1 exposure causes a dose dependent inhibition of alkaline phosphatase 
activity. Panel b: Immunodepletion of Dkk-1 from MG63 OS conditioned medium 
through incubation with a polyclonal antibody against Dkk-1. The Dkk-1:antibody 
complexes were removed from the medium by protein A affinity chromatography, then 
the medium was assayed by ELISA. Panel c: Osteogenic differentiation by MSCs in the 
presence of non-depleted and Dkk-1 immuno-depleted conditioned medium from MG63 
OS cells. Representative results from one of three donors are presented. Measurements 
were achieved by ALP assay, values represent the mean (n=6), and error bars represent 
standard deviations. P values were calculated by 2-tailed Student’s t-test. Panel d: 
Osteogenic differentiation by MSCs in the presence of Dkk-1 and with or without the 
GSK3β inhibitor BIO. Panel e: The effect of a range of BIO doses on the proliferation of 
osteosarcoma cells. Cell numbers were evaluated by fluorescent nucleic acid intercalation 
assay. 
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Figure 3: Panel a: Fluorescence activated cell sorting of transduced cells expressing 
mitochondrially localized red fluorescent protein. The cells from the gate designated M1 
were used in subsequent experiments. Panel b: Micrographs of the labeled MG63 OS 
cells. Panel c: Micrographs of the tumorspheres derived from culture in clotted human 
plasma. Panel d: A sectioned tumorsphere (red) immuno-stained for the detection of 
Dkk-1 (green). Nuclei are stained with DAPI (blue). The isotype control is presented on 
the right. 
 
Figure 4: Panel a: Live animal fluorescence imaging of an implanted construct 
containing labeled MG63 OS cells. Panel b: Evaluation of human Dkk-1 levels in the 
blood of implanted animals after 1 week. The x-axis represents the initial number of 
implanted cells. Measurements were achieved by ELISA assay on mouse serum, values 
represent the mean (n=4, 2 males and 2 females), and error bars represent standard 
deviations. P values were calculated by 2-tailed Student’s t-test. 
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